Novavax, Inc. (NASDAQ:NVAX) Receives $18.33 Consensus Target Price from Analysts

Shares of Novavax, Inc. (NASDAQ:NVAXGet Free Report) have been given a consensus rating of “Hold” by the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $18.83.

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Monday, August 12th. B. Riley restated a “buy” rating and issued a $26.00 price objective (up from $23.00) on shares of Novavax in a research note on Thursday, October 10th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $31.00 target price on shares of Novavax in a report on Wednesday, October 2nd.

Get Our Latest Report on Novavax

Institutional Investors Weigh In On Novavax

A number of hedge funds and other institutional investors have recently bought and sold shares of NVAX. Coatue Management LLC acquired a new stake in shares of Novavax in the 4th quarter worth approximately $7,294,000. China Universal Asset Management Co. Ltd. grew its stake in Novavax by 95.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 26,878 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 13,135 shares during the last quarter. TSP Capital Management Group LLC increased its holdings in Novavax by 23.9% during the 1st quarter. TSP Capital Management Group LLC now owns 1,376,950 shares of the biopharmaceutical company’s stock valued at $6,582,000 after acquiring an additional 265,250 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Novavax by 17.1% in the first quarter. Swiss National Bank now owns 211,000 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 30,800 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Novavax in the first quarter valued at approximately $1,499,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Trading Up 0.7 %

Shares of NASDAQ NVAX opened at $12.62 on Thursday. The stock has a fifty day simple moving average of $12.47 and a 200-day simple moving average of $11.57. Novavax has a twelve month low of $3.53 and a twelve month high of $23.86. The stock has a market capitalization of $1.77 billion, a PE ratio of -3.98 and a beta of 2.04.

Novavax (NASDAQ:NVAXGet Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.82 by ($0.83). The company had revenue of $415.50 million for the quarter, compared to analysts’ expectations of $458.57 million. During the same period in the prior year, the firm posted $0.58 EPS. The company’s quarterly revenue was down 2.1% on a year-over-year basis. On average, equities analysts predict that Novavax will post -0.97 earnings per share for the current year.

Novavax Company Profile

(Get Free Report

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Further Reading

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.